Medical Advocates for Social Justice

   Medical Advocates for Social Justice

Kaletra Library Service 
 Conference Abstracts and Posters
   

 Index of  Abstracts and Posters from 

  8th Conference on Retroviruses and 
  Opportunistic  Infections.  

  Chicago, IL  USA     

 
  February 04 – February 08, 2001
KLS Main Page  KLS Conference  Index  Home

Last updated:  December 22, 2005
Special Reports
 

CONFERENCE POSTER
Results from the Kaletra  Early Access Program
Reitmayer R, Rode R, Bernstein B, et al
Poster   Abstract

In Vitro Studies
 

CONFERENCE POSTER
Protein Binding of Lopinavir (LPV) and Ritonavir (RTV): In Vitro and Ex Vivo
Data from HIV-infected Patients and Healthy Volunteers
Hsu A, Bertz R, Hickman D, et al
Poster   Abstract
Resistance
 

CONFERENCE POSTER
Patterns of Protease Inhibitor Cross Resistance in Viral Isolates with Reduced
Susceptibility to Lopinavir
Brun S, Kempf D, Isaacson J, et al.
Poster   Abstract

CONFERENCE POSTER
Absence of Resistance to Lopinavir/r (formerly known as ABT-378/r) Observed
Through 48 Weeks of Therapy in Antiretroviral-Naïve Subjects (M98-863 Study)
 Bernstein B, Moseley J, Kempf D, et al.
Poster   Abstract

Viral Dynamics/Response
 

Using Viral Dynamics To Document the Greater Antiviral Potency of a
Regimen Containing Lopinavir/Ritonavir, Efavirenz, Tenofovir, and
Lamivudine Relative to Standard HAART.
Louie M, Ramratnam B, Kost R, et al
 Abstract

Latent Reservoir and Residual HIV-1 Replication on Antiretroviral Therapy
Ho D, Ramratnam B, Louiie M, Markowitz, M 
Abstract

Pediatric Treatment Indications
 

LPV/RTV

Kaletra  (ABT-378/ritonavir) in HIV-Infected Children at 48 Weeks
Saez-Llorens X, Renz C, Deetz C,
Abstract

CONFERENCE POSTER
Kaletra (ABT-378/ritonavir) in HIV-Infected Children at 60 Weeks
Saez-Llorens X, Renz C, Deetz C,  et al.  
 Poster   
 Adolescent/Adult Treatment Indications
 

LPV/RTV vs NFV in ART-Naïve Patients

  CONFERENCE POSTER
Comparison of Time to Achieve HIV RNA <400 copies/mL and <50
copies/mL in a Phase III, Blinded, Randomized Clinical Trial of Kaletra vs.
NFV in ARV-Naïve Patients
King M, Bernstein B, Kempf D, et al
 Poster   Abstract 		 

LPV/RTV/EFV in Multiple PI-Experienced/NNRTI-Naive Patients

  CONFERENCE PRESENTATION
Kaletra (ABT-378/ritonavir) and Efavirenz: 48-Week Safety/Efficacy/Pharmacokinetic Evaluation in Multiple PI-Experienced Patients 
Clumeck N, Brun S, Sylte J, et al.
 Oral Presentation   Abstract		  

KLS Main Page  KLS Conference  Index  Home

8th Conference on Retroviruses and Opportunistic Infections 
KLS Index
© 2001/2002 Medical Advocates for Social Justice